BioSpace News Archive

Celcuity Inc. announced that it plans to initiate a Phase 3 clinical trial to evaluate gedatolisib plus a CDK4/6 inhibitor and fulvestrant as first-line treatment for patients with HR+/HER2- advanced breast cancer who are endocrine therapy resistant.

SERB Pharmaceuticals has appointed Vanessa Wolfeler as its new Chief Executive Officer (CEO) effective 3 June 2024.

Bio-Techne Corporation will showcase multiple applications of its recently launched MauriceFlex™ System at the 72nd ASMS Conference on Mass Spectrometry and Allied Topics, taking place June 2nd-6th in Anaheim, California.

BioLineRx Ltd. today announced a multi-center Phase 1 clinical trial sponsored by St. Jude Children’s Research Hospital, Inc. to evaluate motixafortide for the mobilization of CD34+ hematopoietic stem cells (HSCs) used in the development of gene therapies for patients with sickle cell disease (SCD).

Compugen Ltd. today announced it is entitled to receive a milestone payment from AstraZeneca (LSE/STO/Nasdaq: AZN) triggered by the dosing of the first patient in a Phase 3 trial evaluating rilvegostomig, AstraZeneca’s PD-1/TIGIT bispecific antibody.

Hudson Therapeutics announced that Shaperon, Inc. and Hudson Therapeutics, Inc. which is the US Subsidiary of Shaperon will attend the upcoming 2024 BIO International Convention June 3 - 6, 2024, in San Diego, California to explore partnering opportunities.

Willow Biosciences Inc. announces a multi-product development and licensing partnership with Laurus Labs.

CareDx, Inc. announced new data to be presented at the 2024 American Transplant Congress being held June 1-5 in Philadelphia.

Jasper Therapeutics, Inc. today announced presentations of data from its preclinical and healthy volunteer studies of briquilimab, as well as trial-in-progress presentations from its BEACON and SPOTLIGHT clinical studies, at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2024, taking place May 31 – June 3 in Valencia, Spain.

Telix Pharmaceuticals Limited today announces additional positive data from the ProstACT SELECT trial (“SELECT”) of TLX591 (177Lu rosopatamab tetraxetan), a lutetium-labelled rADC therapy for the treatment of adult patients with PSMA-positive metastatic castrate-resistant prostate cancer (mCRPC).